ACHE and early-onset autosomal dominant Alzheimer disease: BYZX [(E)-2-(4-((diethylamino)methyl)benzylidene)-5,6-dimethoxy-2,3-dihydroinden-one] was one of the synthetic acetylcholinesterase (AChE) inhibitors selected for the treatment of Alzheimer’s disease symptoms [1].